低浓度化学药物配合淋巴因子激活的杀伤细胞对人卵巢癌细胞体外 …

探讨低浓度化学药物配合淋巴因子激活的杀伤细胞能否增强对卵巢癌细胞的体外杀伤敏感性。方法应用１．５μｇ／ｍｌ泰素４μｇ／ｍｌ顺铂、２５μ／ｍｌ氟尿嘧啶,与人卵巢癌细胞系ＳＫＯＶ３作用１８小时后,采用＾５１Ｃｒ释放法,观察ＳＫＯＶ３对被白细胞介素２激活的ＬＡＫ细胞的杀伤敏感性;

Cytotoxicities of low dose anticancer agents combining lymphokine activated killer cell against ovarian adenocarcinoma cell line SKOV3

OBJECTIVE: To investigate whether low-dose anticancer agents could increase the sensitivity of ovarian adenocarcinoma cell line SKOV3 to lymphokine activated killer cell (LAK). METHODS: After SKOV3 cells were pretreated by low dose anticancer agents Taxol, cis-diamminedichloroplatin(CDDP), 5-fluorouracilum(5-FU) for 18 hours, the sensitivity of SKOV3 to LAK was detected by four 51Cr release assay. And the percentage of SKOV3 adhesion to LAK and intercellular adhesion molecule-1 (ICAM-1) expression on SKOV3 were detected by improved Grimm's assay and FACS respectively. RESULTS: After pretreatment of SKOV3 cell with 1.5 micrograms/ml Taxol, 4 micrograms/ml CDDP, 25 micrograms/ml 5-FU or without anticancer agents as control for 18 hours, the cytotoxicities of Interleukin-2 activated LAK against them were 29.7%, 45.9%, 37.2% and 28.5% respectively. The conjugation rates of SKOV3 and LAK were 20.1%, 26.1%, 24.9% and 18.7% respectively. The positive rates of ICAM-1 expression were 52.5%, 65.5%, 68.1% and 49.7% respectively. CDDP and 5-FU increased ICAM-1 expression significantly and the sensitivity of SKOV3 cell to LAK cell lysis was well related to the ICAM-1 expression. CONCLUSION: The results indicate that some low dose anticancer agents can increase the sensitivity of cancer cells to LAK cells and it would be useful in clinical practice.